Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma

• Published in: Clinical cancer research Vol. 2; no. 10; pp. 1781 - 1785
• Main Authors: FURIHATA, M, ISHIKAWA, T, INOUE, A, YOSHIKAWA, C, SONOBE, H, OHTSUKI, Y, ARAKI, K, OGOSHI, S
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01-10-1996
• Subjects: Aged; Biological and medical sciences; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - pathology; Cyclin A - biosynthesis; Data Interpretation, Statistical; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - pathology; Esophagus; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Immunohistochemistry; Male; Medical sciences; Middle Aged; Prognosis; Severity of Illness Index; Survival Analysis; Tumors; Human; Immunohistochemistry; Squamous cell carcinoma; Prognosis; Esophageal disease; Gene overexpression; Cyclin; Malignant tumor; Gene expression; Esophagus; Pathology; Digestive diseases; Nuclear protein
• ISSN: 1078-0432; 1557-3265

The expression of cyclin A protein was retrospectively investigated in 124 patients with human esophageal squamous cell carcinoma
with immunohistochemical techniques using antibody to cyclin A protein (BF683). Of 124 tumors, 49 (39.5%) exhibited positive
staining in cancer cells with this antibody. Staining was observed predominantly but not exclusively in the nucleus. A significantly
higher degree of association of immunoreactivity with this antibody was detected for advanced types of tumors (stages I, II,
III, and IV) than for early tumors (stage 0; P < 0.05). Patients with cyclin A immunopositivity had a significantly poorer
survival rate than did other patients (P < 0.01). These findings provide the first evidence for frequent and unscheduled overexpression
of cyclin A protein in human esophageal cancer and suggest the possibility that alteration of cyclin A overexpression is associated
with tumor progression and patient prognosis for esophageal cancers.